Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Mapi Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Copaxone Depot, a long-acting glatiramer acetate designed to be administered as an intramuscular injection, is being investigated as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis (RMS).
Product Name : WhisperJECT
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 08, 2023
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Mapi Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Copaxone (glatiramer acetate) its ability to induce the peripheral Th2 cells and their subsequent crossing of the blood barrier allows for the reduction of further inflammation within the CNS.
Product Name : Copaxone
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2023
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
COPAXONE® Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis
Details : The label update of COPAXONE® (Glatiramer Acetate) follows the review of clinical and non-clinical evidence, including latest data from the COBRA study that investigated safety outcomes in infants breastfed by mothers with MS undergoing GA treatment dur...
Product Name : Copaxone
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2022
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Viatris
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study evaluating a long-acting glatiramer acetate (copaxone) injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 percent compared to placebo.
Product Name : GA Depot
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Viatris
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : At AAN, company will be presenting 5 year data from Phase IIa study in RRMS. Also, the results seeN in the ongoing Phase II study for GA Depot in primary progressive MS (PPMS) patients, to be presented at the meeting as plan to initiate a Phase-3 for PPM...
Product Name : GA Depot
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2022
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GA Depot is a long-acting injection version of the approved Copaxone® (Glatiramer Acetate) designed to be administered as an intramuscular injection once every four weeks, is being evaluated for treatment of relapsing forms of multiple sclerosis.
Product Name : GA Depot
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2022
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Patients were eligible for the study if they were diagnosed with relapsing MS (RMS), gave a live birth, were breastfeeding under GA treatment (COPAXONE® 20 or 40 mg/mL) or breastfeeding under no DMT treatment.
Product Name : Copaxone
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A non-interventional analysis of the study found no evidence of safety concerns in infants born to mothers with multiple sclerosis (MS) who were breastfeeding and receiving glatiramer acetate (GA) treatment.
Product Name : Copaxone
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2021
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Mapi Pharma Engages PRA Health Sciences as CRO for Phase III Multiple Sclerosis Trial
Details : GA Depot is a long-acting version of Teva Pharmaceutical’s Copaxone (glatiramer acetate). Mapi Pharma is working with the CRO PRA Health Sciences for its Phase III trial investigating glatiramer acetate depot (GA Depot) for relapsing forms of multiple ...
Product Name : GA Depot
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2021
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Viatris
Deal Size : Inapplicable
Deal Type : Inapplicable
Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial
Details : GA Depot is a long acting injection version of the approved Glatiramer Acetate products (Copaxone® and its generic versions) for treating multiple sclerosis (RMS), designed to be administered as an intramuscular injection once every four weeks.
Product Name : GA Depot
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2020
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Viatris
Deal Size : Inapplicable
Deal Type : Inapplicable